Andrew Meadow

For over 27 years, Andrew has achieved a significant track record of success within three critical areas of healthcare innovation: overseeing and advancing novel therapeutics and medical technologies from inception to NDA approval; executing complex corporate development transactions including capital formation, alliance management, and acquisitions; and venture finance and initial company creation. Prior to founding Health Innovation Capital, Andrew was a Partner at Excelyrate Capital Fund I, during which time he was responsible for: 1) building a pipeline of potential investment opportunities; 2) expanding and managing syndicate relationships,; 3) creating a healthcare centric venture portfolio that yielded significant returns to LPs, established a collection of investments that are either standards of care or best in class within their respective therapeutic areas. During his tenure, he created a proprietary set of integrated search, evaluation, and risk assessment methodologies and tools that have received praise within both the entrepreneur and venture communities. As a Principal investor with Essex Woodlands, the Michigan Economic Development Corp’s Life Science Venture Fund, and Excelyrate Capital, Andrew’s investing experience included the execution of 11 investments with 10 Exits that achieved a track record for providing significant collective net cash on cash returns for investors and exits that included 7 IPOs and 3 acquisitions. Andrew’s tenure as a senior healthcare financial, business development and commercial strategy executive includes multinational experiences in both Large Cap pharma (Baxter) and rapid growth venture backed biotech and medtech companies including SkinAxis (SVP Commercial Operations and Corp. Strategy) and Conceivex, Inc. (Chief Strategy and Business Development Officer). During this tenure, he was responsible for originating and negotiating several multi-million dollar strategic partnerships, co-development/marketing alliances, and inorganic pipeline growth initiatives that yielded significant shareholder value. He was responsible for leading the commercialization of three (3) products, which grew from $0.00 gross revenues to between $85 to $250M respectively after 18 months of his leadership. As a C-Suite executive, Andrew has successfully led three healthcare companies to successful M&A exits at significant multiples to EBIDTA. During his tenure at UBS Warburg, Andrew worked on a number of market leading biotech and medtech transactions, with over $10 BN in IPO, M&A, and Equity/Debt financing transactions executed. Andrew is a key opinion leader in pediatric health innovation and venture capital investment targeting that patient population frequent speaking internationally on such topics as risk management, program and new product planning, early stage capital formation strategies, and healthcare commercial innovation strategy. In addition, Andrew has worked with the National Institute of Health (NIH) and nationally recognized indication specific advocacy groups.